Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]EDP-938 in Healthy Males
NCT04927793Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zelicapavir in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of EDP-938 up to 11 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-tlast) of EDP-938 up to 11 days and 4 more. Started May 2021; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04927793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927793.